Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

作者：Lina Lin, Weixia Nong, Bin Luo, Yingying Ge, Xia Zeng, Feng Li, Rong Fan, Qingmei Zhang, Xiaoxun Xie · 发表于：Immunity Inflammation and Disease · 年份：2021 · DOI：10.1002/iid3.534 · 被引用次数：10 · 研究领域：Immunotherapy and Immune Responses、Toxin Mechanisms and Immunotoxins、Reproductive System and Pregnancy

INTRODUCTION: Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). METHODS: The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme-linked immunosorbent assays (ELISA), the level of ACRBP in cell-cultured medium was also tested. RESULTS: ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti-ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708-0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan-Meier analysis revealed that the overall survival (OS) and disease-free surv...